Skip to main content
Drug bottle and Pill

Compare Skyrizi vs. Bimzelx

Head-to-head comparisons of medication uses, side effects, warnings, and more.

Key takeaways

Skyrizi (risankizumab) and Bimzelx (bimekizumab) are both medications used to treat moderate-to-severe plaque psoriasis and psoriatic arthritis in adults and belong to the interleukin antagonist medication class. However, they have several differences. Skyrizi is also FDA-approved for ulcerative colitis and Crohn's disease, while Bimzelx is approved for non-radiographic axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa. Skyrizi is administered as an injection every 2 or 3 months after initial doses, whereas Bimzelx is injected every month initially and then every other month. Skyrizi is available as a prefilled syringe, pen, and On-Body Injector, while Bimzelx comes as prefilled autoinjectors and syringes. Common side effects of Skyrizi include joint pain and a higher risk of infections, while Bimzelx may cause runny nose, cough, and oral thrush. Both medications require caution with live vaccines due to their effects on the immune system.

Browse medications

View All

Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.